Market crushed
- Thread starter Jazz4ever
- Start date
JohnStockalypse
Well-Known Member
This is why Karl Malone keep all money in shoe.
We should just take the pain in one big punch to the gut, and move on from there instead of taking 50 smaller punches to the face and trying to smile.
The quick fix garbage will never work, we a long term fix to our long term problem(s).
The quick fix garbage will never work, we a long term fix to our long term problem(s).
InGameStrategy
Well-Known Member
The job numbers will not provide relief.
The debt ceiling deal is expected to cost the U.S. economy anywhere from several thousand jobs to (according to the Economic Policy Institute) nearly two million jobs.
Until the American people insists on increases in tax revenue (starting with the wealthy and the corporations, who are currently enjoying decades-low tax rates and record cash levels but aren't using their cash to hire people) so that the billions being hoarded is actually injected into the economy, expect the economy to continue to sputter.
Oh--and btw--graduate students (some of whom develop and implement economy-building technical expertise) will suffer from the economy also.
I saw that. One of the random fluctuations of demography means that if I pursued the same career path some six years later my loans would cost me an extra $12,000 now.
The Thriller
Well-Known Member
Other than giving away billions to corporations, banks, and wall street, what other gimmicks has our government really tried to get us out of this craphole?
Extending unemployment benefits, sending out checks, reducing our income tax with-holdings, public works projects...
The Thriller
Well-Known Member
Sending out checks? That's normal. Extending unemployment benefits? That's tiny in scale and wasn't supposed to jump start the economy. All the other stuff wasn't meant to do much. What public works are you talking about?
North Dakota, Montana, and Wyoming. Lots of jobs up there.
You can't forget Texas.
I've been in an oil company "war room" with maps all around on all the walls, and have had it explained to me. Our corporate "foreign policy" has been "USE THEIRS FIRST".
We made the Grand Staircase a national "monument" to keep the Dutch corporation from shipping it all to Indonesia to corner the Asian market.
There's as much oil in New Mexico as Texas, and as much in the northern plains as Saudi Arabia. . . . and more in the Gulf.
We have more natural gas than oil, and it burns cleaner, but if we switch over to natural gas before we use all the Mideast oil, we're long-term "vulnerable" to the development of actual competition in the oil industry which would disappoint our cartelists.
A
Agoxlea
Guest
The job numbers looked pretty good. Not good enough to erase yesterday's losses, but still.
Duck Rodgers
Well-Known Member
No worries, guys. Osama Ben Bernanke and Timothy Mcveigh Trichet have it all figured out:
https://blogs.forbes.com/steveschaefer/2011/08/05/report-ecb-ready-to-buy-italian-spanish-bonds/
What do they call doing the same thing over and over again and expecting different results? Insanity or something like that?
https://blogs.forbes.com/steveschaefer/2011/08/05/report-ecb-ready-to-buy-italian-spanish-bonds/
What do they call doing the same thing over and over again and expecting different results? Insanity or something like that?
Last edited:
Mission Accomplished
Well-Known Member
Well, we could alway cut more jobs and try to reduce our deficit instead of creating jobs and increasing our GDP which could bring us faster out of debt.
Duck Rodgers
Well-Known Member
Biotech is a good way to lose money too. See what happened to DNDN yesterday as a prime example. Any little problem with your companies' drug, and your stock gets halved at best instantly.
Last edited:
Dendreon is a client so I can't comment too much on this stock but I want to address one thing: There is no problem with Provenge, there is a problem with the present size of the market for Provenge relative to previous expectations. It's a sales issue, not a problem with the company's drug.
It also doesn't help that it's a drug that has a very different procedure than reimbursement rules contemplate and we're presently operating in a period of time where reimbursement rules are in flux, not the least of which is the result of the things happening in Washington.
Duck Rodgers
Well-Known Member
Correct. I was including ANY problem with the drug in my mind when I wrote that, not just issues with the drug itself. But that clarification definitely helps.
That's almost worse though because if you were getting in DNDN at this point with all the trials and FDA approval out of the way, you're probably thinking you're in a pretty stable biotech stock. But hey, that's the risk you take on any stock that only has one main money maker I guess.